The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?

Addiction

Volumn 110, Issue 6, 2015, Pages 984-985

  Hellard, Margaret ^a   Scott, Nick ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

Hepatitis C; Modelling; People who inject drugs; Treatment

Indexed keywords

HEPACIVIRUS; HEPATITIS C; HUMAN; SUBSTANCE ABUSE;

HEPACIVIRUS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84929105015     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12912     Document Type: Note

References (14)

1. Doyle J. S., Aspinall E., Liew D., Thompson A. J., Hellard M. E. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013; 75: 931-43.
2. Edlin B. R. Perspective: test and treat this silent killer. Nature 2011; 474: s18-19.
3. Hagan L. M., Wolpe P. R., Schinazi R. F. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013; 21: 625-33.
4. Hellard M., Doyle J. S., Sacks-Davis R., Thompson A. J., McBryde E. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology 2014; 59: 366-69.
5. Hill A., Khoo S., Fortunak J., Simmons B., Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014; 58: 928-36.
6. Martin N. K., Vickerman P., Grebely J., Hellard M., Hutchinson S. J., Lima V. D. et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.
7. de Vos A. S., Prins M., Kretzschmar M. E. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction 2015; 110: 975-83.
8. Hellard M., Rolls D. A., Sacks-Davis R., Robins G., Pattison P., Higgs P. et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014; 60: 1861-70.
9. Brener L., Horwitz R., von Hippel C., Bryant J., Treloar C. Discrimination by health care workers versus discrimination by others: countervailing forces on HCV treatment intentions. Psychol Health Med 2015; 20: 148-53.
10. Rhodes T., Harris M., Martin A. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. Sociol Health Illn 2013; 35: 1023-44.
11. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
12. Pham S. T., Bull R. A., Bennett J. M., Rawlinson W. D., Dore G. J., Lloyd A. R. et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 2010; 52: 1564-72.
13. Sacks-Davis R., Aitken C. K., Higgs P., Spelman T., Pedrana A., Bowden S. et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLOS ONE 2013; 8: e80216.
14. Aspinall E. J., Corson S., Doyle J. S., Grebely J., Hutchinson S. J., Dore G. J. et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57: S80-89.